Longevity

ESC 2025 delivered first KARDIA-3 results for zilebesiran and a green light from Roche and Alnylam for ZENITH, a global cardiovascular outcomes trial. Here is what twice yearly blood pressure control could mean for adherence, safety, healthspan, and equity.

A February 25, 2025 first in human readout showed lineage specific telomere elongation after an autologous ZSCAN4 cell therapy in patients with telomere biology disorders. Here is what that signal means, the real risks, and the milestones to watch over the next two years.

In 2025, PCSK9 moved from target to strategy. Verve's in vivo base edit delivered dose dependent LDL cuts while oral PCSK9 pills from AstraZeneca and Merck posted pivotal wins, setting up a permanence versus reversibility showdown.

Outcomes data and payer shifts have turned GLP-1s into a population health tool. Here is the biology, the care models, and the metrics that turn pounds into years lived better.

Three credible trials are dragging senolytics out of mouse lore and into human data. St. Jude pits dasatinib plus quercetin against fisetin, Washington University runs SToMP-AD in early Alzheimer’s, and NIH backs a frailty study in people aging with HIV. Intermittent pulse dosing, functional endpoints like gait speed, and on-target biomarkers could make 2025 the pivot year.

With the FDA’s first efficacy green light for a canine anti aging pill and a revived NIH backed rapamycin trial, companion dogs are becoming the de risked bridge to human geroprotectors. Here is the biology, the regulatory playbook, and what to watch next.

A March 31, 2025 court decision vacated FDA’s LDT rule. On September 19, 2025, FDA formally rescinded it, putting aging tests back under CLIA and shifting the strategy for endpoints, payers, and trial design.

Starting in January 2025, UK Biobank began profiling thousands of plasma proteins across 500,000 participants. The dataset could validate or retire today’s aging clocks, enable earlier disease prediction, and set a higher evidence bar for longevity care.

Fresh primate and liver data from Life Biosciences suggest controlled OSK gene therapy can drive repair without erasing cell identity. Here is what the early 2026 optic neuropathy studies must prove, the safety controls to watch, and the biomarkers that will make or break the program.

A randomized human study in 2025 reports that therapeutic plasma exchange, especially paired with IVIG, lowered multiple epigenetic aging clocks. We unpack mechanisms, durability, safety, costs, and the decisive trial that could prove real longevity benefits.

With the FDA clearing the first clinical trials of pig-to-human kidneys and a second living-recipient transplant at Mass General, xenotransplantation just moved from theory to clinic. Here is how it could change lifespan and healthspan, and what to watch next.

Retro Biosciences plans to dose its first human study of RTR242, an autophagy-boosting Alzheimer’s pill, in Australia by late 2025. Here is why the pathway matters, the biomarkers to watch, and how this bet could reshape longevity biotech.

Retro is steering its first human study to Australia, using Alzheimer’s as a clinical beachhead for RTR242, an autophagy‑boosting pill that could translate longevity biology into medicine faster.

On July 25, 2025, Lilly closed its Verve acquisition, betting that in vivo base editing of PCSK9 could replace decades of statins with a single infusion. Early Phase 1b data show up to 69% LDL-C reductions, FDA Fast Track, and Phase 2 on deck.

Fresh signals from EASD 2025 and a large Medicare analysis suggest GLP-1 therapies cut near-term cardiovascular events and deaths. With potent oral versions on the way, adherence and access could surge, reshaping budgets and the definition of a longevity therapy.

In 2025, the first human data for in vivo PCSK9 base editing showed large, durable LDL-C drops after a single infusion. If safety holds and access follows, one-and-done edits could shift heart disease prevention from chronic care to permanent risk cut.

Retro Biosciences is set to begin first human testing in Australia of RTR242, an autophagy-activating pill aimed at Alzheimer’s. Paired with OpenAI’s GPT‑4b micro reprogramming work, it is a pivotal test for geroscience in the clinic.

Retro Biosciences will dose its first Alzheimer’s patients in Australia with RTR242, an autophagy-boosting pill. The study is a test case for proving longevity mechanisms through disease endpoints, and for a new path in regulation and funding.